Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.33B +453.0% |
| Revenue (ttm) | 504.60M +16.8% |
| Net Income | -241.15M |
| EPS | -1.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 89.20 |
| Previous Close | 90.65 |
| Day's Range | 88.66 - 90.59 |
| 52-Week Range | 15.88 - 95.49 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Arrowhead price target raised to $120 from $115 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $120 from $115 and keeps a Buy rating on the shares. The firm cites the one quarter pull-forward in…
Arrowhead price target raised to $104 from $98 at Stifel
Stifel raised the firm’s price target on Arrowhead (ARWR) to $104 from $98 and keeps a Buy rating on the shares.
Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2026
Strong phase III results in SHTG and expanding REDEMPLO launch drove revenue growth, with commercial and R&D investments increasing expenses. Priority review voucher acquisition aims to accelerate SHTG approval, while a robust pipeline and global infrastructure support future growth.
Arrowhead Pharmaceuticals Quarterly report: Q3 2026
Arrowhead Pharmaceuticals has published its Q3 2026 quarterly earnings report on August 4, 2026.
Arrowhead Pharmaceuticals Earnings release: Q3 2026
Arrowhead Pharmaceuticals released its Q3 2026 earnings on August 4, 2026, summarizing the period's financial results.
Arrowhead reports Q3 EPS ($1.36), consensus ($1.23)
Reports Q3 revenue $75.25M, consensus $44.01M. The company said, “The recent period for Arrowhead (ARWR) included transformational events that support continued growth. We recently announced topline r...
Arrowhead acquires FDA priority review voucher
Arrowhead (ARWR) Pharmaceuticals announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review V...
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is host...
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and D...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Co...
Arrowhead price target raised to $123 from $101 at B. Riley
B. Riley raised the firm’s price target on Arrowhead (ARWR) to $123 from $101 and keeps a Buy rating on the shares.
Arrowhead completes enrollment in Phase 3 YOSEMITE trial
Arrowhead (ARWR) Pharmaceuticals announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA iHnterference, RNAi, therapeut...
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran,...
Arrowhead price target raised to $115 from $100 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $115 from $100 and keeps a Buy rating on the shares. The firm says the SHASTA Phase 3 data…
Arrowhead price target raised to $120 from $100 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $120 from $100 and keeps an Overweight rating on the shares. The firm increased its view of the odds…
Arrowhead price target raised to $126 from $110 at Piper Sandler
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $126 from $110 and keeps an Overweight rating on the shares. The Phase III SHASTA-3 and…
Arrowhead price target raised to $115 from $90 at Chardan
Chardan analyst Keay Nakae raised the firm’s price target on Arrowhead (ARWR) to $115 from $90 and keeps a Buy rating on the shares after the company reported that both…
Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results
Arrowhead Pharmaceuticals stock saw major gains after the company announced new results from a Phase 3 trial.
Arrowhead announces Phase 3 SHASTA-3, SHASTA-4 met primary endpoint
Arrowhead (ARWR) Pharmaceuticals announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia, a condition that si...
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discus...
Arrowhead price target raised to $95 from $88 at JPMorgan
JPMorgan raised the firm’s price target on Arrowhead (ARWR) to $95 from $88 and keeps an Overweight rating on the shares. The company’s SHASTA-3/4 readout in severe hypertriglyceridemia remains one…
Arrowhead initiated with a Buy at Stifel
Stifel analyst James Condulis initiated coverage of Arrowhead (ARWR) with a Buy rating and $98 price target. SASHTA-3/4 results should establish plozasiran as “a best-in-class drug,” argues the analys...